Market Watch Highlights: Immunovant Inc (IMVT) Ends on an Downturn Note at 29.93

For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Immunovant Inc’s stock clocked out at $29.93, down -4.74% from its previous closing price of $31.42. In other words, the price has decreased by -$4.74 from its previous closing price. On the day, 0.75 million shares were traded. IMVT stock price reached its highest trading level at $31.66 during the session, while it also had its lowest trading level at $29.66.

Ratios:

To gain a deeper understanding of IMVT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.08 and its Current Ratio is at 13.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

On October 09, 2024, Oppenheimer reiterated its Outperform rating and also lowered its target price recommendation from $47 to $53.

On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $50.Oppenheimer initiated its Outperform rating on March 28, 2024, with a $50 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 23 ’24 when Levine Mark S. sold 4,361 shares for $29.53 per share. The transaction valued at 128,780 led to the insider holds 322,878 shares of the business.

Geffner Michael sold 3,189 shares of IMVT for $94,171 on Oct 23 ’24. The Chief Medical Officer now owns 134,971 shares after completing the transaction at $29.53 per share. On Oct 23 ’24, another insider, Stout Jay S, who serves as the Chief Technology Officer of the company, sold 2,740 shares for $29.53 each. As a result, the insider received 80,912 and left with 142,186 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMVT now has a Market Capitalization of 4380764672 and an Enterprise Value of 4038926848.

Stock Price History:

Over the past 52 weeks, IMVT has reached a high of $45.58, while it has fallen to a 52-week low of $24.67. The 50-Day Moving Average of the stock is 0.54%, while the 200-Day Moving Average is calculated to be -1.51%.

Shares Statistics:

It appears that IMVT traded 849.61K shares on average per day over the past three months and 627150 shares per day over the past ten days. A total of 145.58M shares are outstanding, with a floating share count of 62.05M. Insiders hold about 57.61% of the company’s shares, while institutions hold 50.75% stake in the company. Shares short for IMVT as of 1728950400 were 12931734 with a Short Ratio of 15.22, compared to 1726185600 on 12458767. Therefore, it implies a Short% of Shares Outstanding of 12931734 and a Short% of Float of 20.21.

Most Popular